Yesterday, Schering-Plough Corp. (SGP) revealed that the European Medicines Agency (EMA) will review its candidate for maintenance treatment of asthma in patients 12 years and above and an oral contraceptive for marketing in Europe. While the fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years and above is currently under review by the U.S. Food and Drug Administration (FDA), the filing for FDA approval of the contraceptive is expected in 2010. The oral contraceptive is a combination of a natural estrogen (which is identical to the estrogen produced by a woman's body) and a selective progestin. The drug was licensed from Merck KGaA. Schering is seeking marketing approval in Europe for the combination to prevent pregnancy. The approval of the combination of mometasone furoate and formoterol fumarate would further consolidate the company’s respiratory portfolio. Asthma, ...

DrStockPick.com Stock Report!

Wednesday August 26, 2009

**************************************************************

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company’s Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older. The company also announced today that the EMEA has validated the MAA for nomegestrol acetate (2.5 mg) / 17 beta-estradiol (1.5mg), a combined oral contraceptive (COC) containing a unique combination of a natural estrogen identical to the estrogen produced by a woman’s own body and a selective progestin

Marathon Oil Corporation (NYSE: MRO) announced today

...